South Korea-based SK Biopharmaceuticals has announced that together with its parent investment company SK Inc., the two companies have participated in a Series D funding for Cala Health, a US bioelectronic medicine leader.

This marks the first time for SK Biopharmaceuticals to invest in the space, paving the way for further strategic partnership and investment in the world’s largest biotech and healthcare market.

SK Biopharmaceuticals said its investment in Cala Health will offer opportunities for potential technology collaboration with the US company in the new neurological space. This will also be a “stepping stone” for the company to further drive innovation in patient access and care.

SK Biopharmaceuticals is currently developing a digital therapeutic device that can detect seizures for patients with epilepsy. This is expected to enter a clinical trial at the end of this year and be previewed at the CES exhibition in Las Vegas next year.

Cala Health is the leader in non-invasive bioelectronic therapy via Cala Trio, a wearable device cleared by the US Food and Drug Administration that is proven to reduce essential tremors and improve patients’ quality of life.